OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has told DirectorsTalk that it is presenting at the European Edition of the Microbiome Summit 2016 in London. The conference will be held at the Holiday Inn in Kensington on the 3rd and 4th November. This is the only conference in Europe dedicated specifically to the microbiome and its development.
The human microbiome has been acknowledged to have significant impact, not only in disease but more importantly in health and wellbeing. Major advances in next generation sequencing technologies have enabled scientific research in connecting an imbalanced microbiome to conditions as diverse as cancer, pulmonary, metabolic, inflammatory and mental/neurodegenerative disease.
The conference is credited for attracting leading research scientists, leading companies in the industry and well connected investment groups, and is a good opportunity to network with like-minded individuals.
The presentation, by Stephen O’Hara, will take place on Friday 4th November and is entitled “Targeted Microbiome Modulation: Next Generation Pre-, Pro-, and Syn-biotics”.
